Anuh Pharma Limited has informed the Exchange regarding Approval from EDQM for CEP of Sulfadimethoxine.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anuh Pharma has received approval from the European Directorate for the Quality of Medicines (EDQM) for the Certificate of Suitability (CEP) of Sulfadimethoxine, an antibiotic API. The CEP certifies that the drug substance meets European Pharmacopoeia standards and is approved for use in medicines marketed in Europe. This regulatory clearance opens the door for the company to supply this product to pharmaceutical manufacturers in European markets. The approval strengthens Anuh Pharma's regulatory portfolio for export-oriented active pharmaceutical ingredients (APIs).
Positive for shareholders as it enhances the company's ability to tap into European markets and may support future revenue growth from API exports, though no immediate financial impact or order value has been disclosed.